Learning that your lymphoma treatment includes a donor bone marrow transplant can be a lot to take in. Hearing about graft-versus-host disease (GVHD) for the first time can make it feel even more uncertain.

GVHD happens when donor immune cells, called T cells, don’t fully recognize your body as their own and begin attacking your healthy cells. It’s a known side effect that may occur in some people who receive an allogeneic (donor) stem cell transplant as part of their lymphoma treatment.

The good news is that care teams have clear, well-established strategies for both preventing and managing GVHD. This article walks through how GVHD prevention works and what treatment options are available if it develops.

Doctors begin working to reduce your risk of GVHD before your transplant even takes place. The two main strategies are finding the closest possible donor match and starting preventive medications — called prophylaxis — from the first day of the transplant process.

Finding the right donor is the first step in lowering your GVHD risk. Doctors use a process called human leukocyte antigen (HLA) typing to measure how closely a potential donor’s immune profile matches yours.

HLA markers are proteins on the surface of most cells in the body. Think of them as a biological ID badge that tells your immune system what belongs and what doesn’t.

Finding an HLA-matched donor — someone whose markers closely mirror yours — is the foundation of your prevention plan. The more of these markers a donor shares with you, the less likely their T cells are to treat your body as foreign.

Doctors typically aim to match eight to 10 of these markers. Using a mismatched or unrelated donor can raise GVHD risk, which your care team will factor into your prevention plan.

Along with donor matching, your care team will prescribe medications to help prevent GVHD before it starts. These medicines often include a combination of immunosuppressive drugs, which help calm the immune system starting at or around the time of your transplant.

The most commonly used regimens pair a calcineurin inhibitor — such as tacrolimus or cyclosporine — with methotrexate or mycophenolate mofetil. Some people receive sirolimus-based regimens instead.

A newer approach called post-transplant cyclophosphamide (PTCy) has also shown strong results. A clinical trial consisting of a three-drug regimen anchored by cyclophosphamide helped 53 percent of people stay both GVHD-free and relapse-free at one year compared to 35 percent with the older two-drug standard. However, this approach is not approved by the U.S. Food and Drug Administration (FDA) for GVHD. When it’s used to help prevent GVHD, it’s considered off-label, meaning it’s being used in a way that isn’t specifically approved by the FDA.

Your day-to-day choices play a meaningful role in GVHD prevention. It’s important that you:

• Take all medications exactly as directed and never stop immunosuppressants suddenly. Always consult your team before adjusting any doses, even if you feel well.
• Keep every scheduled lab visit and clinic appointment, including ones that feel routine.
• Report any new or unusual symptoms — especially skin changes, mouth sores, or digestive issues — to your transplant team right away.
• Follow your care team’s guidance to prevent infection, including frequent handwashing, avoiding crowds, and following food safety guidelines.

Managing GVHD treatment is a significant part of life after a bone marrow transplant — and knowing what to expect can make the process feel more manageable. If GVHD does develop, your care team will take a step-by-step approach, starting with the gentlest effective option and adjusting as needed.

For mild GVHD limited to the skin, topical corticosteroids — creams or ointments applied directly to the affected area — are typically the first treatment. On lighter skin tones, a GVHD rash may appear as redness or faint pink patches, similar to a mild sunburn. On darker skin tones, it may show up as deeper discoloration or changes in skin texture.

When GVHD is more widespread — involving the gut, liver, or a larger area of skin — systemic corticosteroids like prednisone or methylprednisolone are the first-line approach. These are taken by mouth or intravenously (through a vein) and work throughout the entire body. Many people respond well to this first step, and the care team will monitor you closely throughout.

Sometimes, GVHD doesn’t improve with corticosteroids. This is known as steroid-refractory GVHD. Roughly 40 percent to 50 percent of people with GVHD may fall into this category. If that happens, your care team has several options to consider.

One common step is adjusting or switching your immunosuppressive medications. Depending on whether your GVHD is acute or chronic and which organs are involved, there are also several FDA-approved targeted therapies that may be recommended. These include medications such as ruxolitinib (Jakafi), ibrutinib (Imbruvica), belumosudil (Rezurock), and axatilimab-csfr (Niktimvo).

Additionally, your care team might recommend a procedure known as extracorporeal photopheresis (ECP), in which your blood is drawn, treated with ultraviolet light outside the body to destroy the activated T cells causing GVHD, and then safely returned.

GVHD can affect different parts of the body, and targeted symptom relief — used alongside your main GVHD medications — can make a real difference in daily comfort. Your care team may recommend the following treatments, depending on which organs are affected.

• Skin — Moisturizing creams and corticosteroid creams may help manage dryness, rash, or skin tightening. Wearing sunscreen with at least SPF 30 may also help protect skin affected by GVHD.
• Mouth — Medicated rinses, such as dexamethasone oral rinse, may help soothe sores and relieve dryness.
• Eyes — Lubricating drops and, in some cases, specialized contact lenses may help ease the dryness and irritation that GVHD can cause in the eyes.
• Gut — Dietary adjustments, nutritional support, and pancreatic enzyme supplements (medicines that help the body break down food) may help when digestion is affected.
• Joints and muscles — Physical therapy may help preserve strength, flexibility, and range of motion, especially when GVHD affects connective tissue.

The medications that treat GVHD work by calming your immune system, but that same effect can make it harder for your body to fight off infections. Close monitoring is especially important after a bone marrow transplant for this reason.

For the first 100 days after an allogeneic transplant, you’ll typically have at least one clinic visit per week. These visits include blood tests and physical exams so your care team can track how your immune system and organs are responding. Your team will watch for early signs of both GVHD and infection and may prescribe preventive antimicrobials, which are medications that help fight germs, during this period.

Your Action Plan

GVHD is a recognized and actively managed side effect for some people who receive a donor bone marrow transplant for lymphoma. Your care team works to prevent it from day one. And if GVHD does develop, there are proven treatment options at every stage.

GVHD is a recognized and well-managed part of the donor transplant journey for lymphoma — whether you’re still weighing your options, preparing ahead of your transplant, navigating recovery, or supporting a loved one through any of these stages. Knowing what to expect and staying closely connected to your care team are two of the most important ways to support yourself after a transplant.

If you haven’t had your transplant yet, write down your questions about donor matching and prophylaxis medications to bring to your next consultation. If you’re in recovery, list your current medications — including doses and timing — and note any changes in your skin, mouth, eyes, or digestion to report at your next visit.

If you’re supporting a loved one, keep a log of any new symptoms you notice and share them with the care team. Your observations can help the team spot changes early.

Your transplant team is your best resource at every stage of this process. Reach out with questions whenever they come up.

Join the Conversation

On MyLymphomaTeam, people share their experiences with lymphoma, get advice, and find support from others who understand.

Have you or a loved one had GVHD after a bone marrow transplant? What helped you work with the care team during prevention or treatment? Let others know in the comments below.